Get the Stockscreener App
19.13
0.26%
-0.05
After Hours:
19.04
-0.09
-0.47%
Organon Co stock is traded at $19.13, with a volume of 2.58M.
It is down -0.26% in the last 24 hours and down -14.41% over the past month.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$19.18
Open:
$19.26
24h Volume:
2.58M
Relative Volume:
1.51
Market Cap:
$4.93B
Revenue:
$6.35B
Net Income/Loss:
$1.05B
P/E Ratio:
8.3537
EPS:
2.29
Net Cash Flow:
$458.00M
1W Performance:
-2.99%
1M Performance:
-14.41%
6M Performance:
+1.76%
1Y Performance:
+10.20%
1-Day Range:
$19.08
$19.35
1-Week Range:
$18.95
$19.83
52-Week Range:
$10.84
$23.10
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Henlius and Organon report successful phase 3 biosimilar trial By Investing.com - Investing.com UK
Organon's SWOT analysis: healthcare firm's stock faces challenges, opportunities By Investing.com - Investing.com UK
Dimensional Fund Advisors LP Buys 463,216 Shares of Organon & Co. (NYSE:OGN) - MarketBeat
Thrivent Financial for Lutherans Lowers Stock Holdings in Organon & Co. (NYSE:OGN) - MarketBeat
AQR Capital Management LLC Has $71.91 Million Stock Holdings in Organon & Co. (NYSE:OGN) - MarketBeat
Why Organon (OGN) Outpaced the Stock Market Today - Yahoo Finance
Organon & Co. (NYSE:OGN) Shares Purchased by Deprince Race & Zollo Inc. - MarketBeat
Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada - Marketscreener.com
Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada – Company AnnouncementFT.com - Financial Times
Organon & Co (OGN) Shares Gap Down to $19.07 on Sep 25 - GuruFocus.com
Are Options Traders Betting on a Big Move in Organon (OGN) Stock? - Yahoo Finance
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
Freshfields advises Roivant in sale of Dermavant to Organon - Legal Desire News Network
Raymond James Increases Reinsurance Group of America (NYSE:RGA) Price Target to $250.00 - MarketBeat
Metric Analysis: Organon & Co. (OGN)’s Key Ratios in the Limelight - The Dwinnex
Rotork plc Continues Share Buyback Program - TipRanks
20,367 Shares in RTX Co. (NYSE:RTX) Acquired by Lombard Odier Asset Management Europe Ltd - Defense World
Reinsurance Group of America, Incorporated (NYSE:RGA) Shares Bought by Canada Pension Plan Investment Board - Defense World
Public Sector Pension Investment Board Acquires 41,954 Shares of Organon & Co. (NYSE:OGN) - MarketBeat
Magnetar Financial LLC Sells 1,825,758 Shares of Organon & Co. (NYSE:OGN) - MarketBeat
RBC says Regeneron reaction to biosimilar court ruling ‘overdone’ - TipRanks
Barclays, Bank of America Helped Orcel Buy Commerzbank Stake - Bloomberg
Rotork Advances Share Buyback Program - TipRanks
Frank Rimerman Advisors LLC Has $1.04 Million Stock Holdings in Organon & Co. (NYSE:OGN) - Defense World
Mizuho recommends buying Corbus following its drop post-Novo's obesity data (NASDAQ:CRBP) - Seeking Alpha
Maternal deaths decline in Jordan - Roya News English
11,412 Shares in RB Global, Inc. (NYSE:RBA) Acquired by Lombard Odier Asset Management USA Corp - Defense World
Organon and Forge Society join forces to promote family planning awareness in Egypt - ZAWYA
Vanguard Personalized Indexing Management LLC Acquires 7,834 Shares of Organon & Co. (NYSE:OGN) - Defense World
Organon: A Surprising Deal (NYSE:OGN) - Seeking Alpha
Ameritas Investment Partners Inc. Has $4.88 Million Stock Position in Reinsurance Group of America, Incorporated (NYSE:RGA) - Defense World
When (OGN) Moves Investors should Listen - Stock Traders Daily
Reinsurance Group of America, Incorporated (NYSE:RGA) Shares Sold by Dimensional Fund Advisors LP - Defense World
Organon & Co. (NYSE:OGN) Shares Sold by Sound Shore Management Inc. CT - MarketBeat
Corbus Pharmaceuticals (NASDAQ:CRBP) Receives “Outperform” Rating from Royal Bank of Canada - Defense World
Insider Selling: Hunt Anthony, Repligen Corp. [RGEN] Director divested 22,191 shares - Knox Daily
Organon (OGN) Gains But Lags Market: What You Should Know - Yahoo Finance
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis - Seeking Alpha
Taking the lead: Organon & Co. (OGN) - SETE News
Rotork plc Conducts Share Buyback and Cancellation - TipRanks
Market Resilience: Organon & Co. (OGN) Finishes Weak at 19.97, Down -2.82 - The Dwinnex
Organon to acquire Dermavant in $1.2B deal - NJBIZ
Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary - Pharmaceutical Technology
Organon to acquire Roivant’s subsidiary Dermavant for $1.2bn - World Pharmaceutical Frontiers
Organon & Co. (NYSE:OGN) Stock Price Down 3.7% - MarketBeat
Organon makes dermatology play with $1.2bn Dermavant buyout - pharmaphorum
Skin deep: Organon buys Dermavant for $1.2B - BioWorld Online
Freshfields advises Roivant in sale of Dermavant to Organon - Freshfields Bruckhaus Deringer
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B - Benzinga
Organon To Buy Psoriasis Treatment Biz For Up To $1.2B - Law360
Organon to acquire Dermavant in back-loaded deal - The Pharma Letter
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.63%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):